Company: KROS
Filing Date: 2025-04-10
Form Type: 8-A12B
Source: 0001664710-25-000035
Chunk: 0

Company: Keros Therapeutics, Inc.
Filing Date: 2025-04-10
Form: 8-A12B
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION
<div align='center'>Washington, D.C. 20549</div>

#### FORM 8-A
<div align='center'>FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF THE

SECURITIES EXCHANGE ACT OF 1934</div>

| Keros Therapeutics, Inc. |

<div align='center'>(Exact name of Registrant as specified in its charter)</div>

| Delaware                                                       |     | 81-1173868                |
| (State of other jurisdiction of incorporation or organization) |     | -I.R.S. Employer I.D. No. |

#### 1050 Waltham Street
<div align='center'>,</div>

#### Suite 302,

#### Lexington
<div align='center'>,</div>

#### Massachusetts
<div align='center'>(Address of principal executive offices)

Securities to be registered pursuant to Section 12(b) of the Act:</div>

| Title of each class             
 each class is to be registered  |     | Name of each exchange on which 
 to be so registered            |
| Preferred Share Purchase Rights |     | The Nasdaq Stock Market LLC    |

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. [X]

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. [ ]

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. [ ]

Securities Act registration statement or Regulation A offering statement file number to which this form relates (if applicable): Not applicable.

Securities to be registered pursuant to Section 12(g) of the Act: None.

## Item 1. Description of Securities to be Registered.
On April 9, 2025, the Board of Directors (the “Board”) of Keros Therapeutics, Inc. (the “Company”), a Delaware corporation, declared a dividend of one preferred share purchase right (“Right”) for each outstanding share of common stock, par value $0.0001 per share, of the Company, and adopted a stockholder rights plan, as set forth in the Rights Agreement, dated as